Astrazeneca Pharma India Ltd Q1 FY27 Results Analysis: PAT Falls 32%, EBITDA Margin Compresses 820 bps

Astrazeneca Pharma India Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 682.79 Cr (+29.72% YoY) and PAT growth of -32.06% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

AstraZeneca Pharma India reported strong 29.7% YoY revenue growth, outpacing the market, with all therapy areas contributing and rare disease emerging as a new driver. However, PAT fell 32.1% due to a severe EBITDA margin compression of 8.2 ppt, driven by inventory drawdown, spike in employee costs from management churn, and forex headwinds. While the manufacturing exit and new product approvals are positive, near-term margin recovery depends on inventory normalization and cost control, with regulatory risk from NPPA demands.

Key Investment Insights

Key Positives

• Revenue from operations grew 29.72% YoY to Rs.682.79 Cr, outpacing the Indian pharmaceutical market growth of ~10-13%.
• All three therapy areas grew: Oncology +26%, Biopharmaceuticals +36%, and Rare Disease ~35x to Rs.14.40 Cr.
• The manufacturing exit was completed, eliminating raw material costs and reducing depreciation by 68.44% YoY.
• Three new CDSCO approvals received in Jun-Jul 2026 (Enhertu expanded indications, Fasenra) support future growth.
• Fifth consecutive quarter of double-digit revenue growth, sustaining the FY26 exit momentum.

Risk Factors

• PAT declined 32.06% YoY to Rs.37.93 Cr despite revenue growth of 29.72% — the widest revenue-to-profit divergence.
• EBITDA margin compressed 8.21 ppt YoY to 7.13%, driven by an inventory drawdown and elevated employee costs.
• Employee costs spiked 73.22% QoQ to Rs.79.16 Cr, partly due to severance from the CFO resignation and five senior exits.
• NPPA demand notices of Rs.148.66 Cr (incl. interest) received post-quarter for Symbicort pricing, representing material contingent liability.
• Related-party transactions remain high at 72.9% of FY25 revenue from AstraZeneca UK and Sweden, with forex headwinds.